A Study to Evaluate Adverse Events and How Single Ascending Doses of ABBV-141 Move Through the Body of Healthy Adult Western and Asian Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 29, 2024

Primary Completion Date

December 30, 2024

Study Completion Date

December 30, 2024

Conditions

Healthy Volunteers

Interventions

DRUG

ABBV-141

Infusion; intravenous (IV)

DRUG

Placebo for ABBV-141

Infusion; IV

DRUG

ABBV-141

Injection; subcutaneous (SC)

DRUG

Placebo for ABBV-141

Injection; SC

Trial Locations (1)

Acpru /Id# 261162, Grayslake